drugset / Trial / NCT01004315

A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder

NCT01004315 ↗

Phase 3 Completed 750 enrolled Kissei Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritobegron Small molecule — —
Comparator Tolterodine Unknown — —

Indications